Actively Recruiting
Phase II Study of Moderate-dose Hypofractionated Radiotherapy with Pembrolizumab for Liver Cancer with Diffuse Tumor Thrombosis in Both Liver Lobes
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2024-04-29
30
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a combination treatment of moderate-dose hypofractionated intensity-modulated radiotherapy and Pembrolizumab in patients with hepatocellular carcinoma that involves diffuse tumor thrombosis in both liver lobes. This Phase II, single-center, open-label study focuses on patients with specific liver tumor volume limits and aims to measure median overall survival as the primary outcome, along with response rates, progression-free survival, and treatment toxicity. Participants receive radiotherapy targeting all tumor lesions with a gross tumor dose of 25Gy over 5 fractions, with a maximum dose of 35Gy at the tumor center. Pembrolizumab is given concurrently at 200mg one week before or during radiotherapy, then continued intravenously every three weeks. Maintenance therapy with Lenvatinib 4mg alongside Pembrolizumab may be provided if suitable, continuing until disease progression or intolerance. Follow-up examinations are scheduled between one and three months after radiotherapy. During the study, participants undergo regular assessments including clinical examinations and monitoring for tumor response and side effects. Key outcomes tracked include overall survival over 24 months, objective response rate within 1 to 3 months post-radiotherapy, progression-free survival, and toxicity up to 24 months. The study involves treatment administration, follow-up visits, and ongoing evaluation to understand how patients respond to this combined therapy approach.
CONDITIONS
Brief Title
Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here